Objective: To evaluate the prognostic value of the depth of lamina propria invasion in patients with T1 bladder cancer. Subjects and Methods: 200 patients were treated between the years 2002 and 2009. Tumours with depth of invasion above the muscularis mucosae level were categorised as pT1a and those with depth of invasion up to or beyond the muscularis mucosae as pT1b. Results: Categorisation for pT1a and pT1b was performed in 176 of 200 patients (88%). In 10 patients a muscle-invasive tumour was found in re-transurethral resection samples. 131 (79%) of 166 analysed patients had pT1a tumour and 35 (21%) had pT1b tumour. During the follow-up, in 101 (61%) patients the tumour had recurred and in 27 (16.3%) the tumour had progressed. Of all the investigated parameters, T1 substaging (p < 0.0001), grade (p = 0.0003) and the number of bacillus Calmette-Guérin instillations (p = 0.0490) were significant in predicting progression. The only significant factor for disease-specific survival was T1 substaging in univariable (p = 0.0008) and multivariable (hazard ratio 4.407) analysis. T1 substaging (p = 0.0149) and tumour multiplicity (p = 0.0448) have a statistically significant prognostic value with respect to overall survival. Conclusions: Deep invasion of the lamina propria is a significant adverse prognostic factor for tumour progression, disease-specific survival and overall survival.

Journal Section:
Editor's choice
Keywords:
T1 substaging, Urothelial carcinoma of the urinary bladder, Recurrence, Progression, Disease-specific survival, Overall survival
1.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-475.
https://doi.org/10.1016/j.eururo.2005.12.031
[PubMed]
2.
Altieri VM, Castellucci R, Palumbo P, Verratti V, Sut M, Olivieri R, Manco R, Ricciardulli S, Nicolai M, Criniti P, Tenaglia RL: Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables. Urol Int 2012;89:61-66.
[PubMed]
https://doi.org/10.1159/000336516
3.
Reljic A, Trnski D: We abandoned ‘superficial bladder cancer': we accepted ‘non-muscle-invasive bladder cancer', but … - on occasion of the 10th anniversary of the first EAU Guidelines on bladder cancer. Urol Int 2012;88:486-487.
[PubMed]
https://doi.org/10.1159/000336514
4.
Dixon JS, Gosling JA: Histology and fine structure of the muscularis mucosae of the human urinary bladder. J Anat 1983;136:265-271.
[PubMed]
5.
Younes M, Sussman J, True LD: The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990;66:543-548.
[PubMed]
https://doi.org/10.1002/1097-0142(19900801)66:3<543::AID-CNCR2820660323>3.0.CO;2-R
6.
Hasui Y, Osada Y, Kitada S, et al: Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994;43:782-786.
[PubMed]
https://doi.org/10.1016/0090-4295(94)90134-1
7.
Holmang S, Hedelin H, Anderstrom C, et al: The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J Urol 1997;157:800-803.
[PubMed]
https://doi.org/10.1097/00005392-199703000-00009
8.
Smits G, Schaafsma E, Kiemeney L, et al: Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 1998;52:1009-1013.
[PubMed]
https://doi.org/10.1016/S0090-4295(98)00374-4
9.
Hermann GG, Horn T, Steven K: The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998;159:91-94.
[PubMed]
https://doi.org/10.1016/S0022-5347(01)64021-7
10.
Babjuk M, Oosterlinck W, Sylvester R, et al: EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2011;59:997-1008.
[PubMed]
https://doi.org/10.1016/j.eururo.2011.03.017
11.
Sobin DH, Wittekind C (eds): TNM Classification of Malignant Tumours, ed. 6. New York, Wiley-Liss, 2002, pp 199-202.
12.
Mostofi FK, Sobin LH, Torloni H: Histopathological typing of urinary bladder tumors; in Mostofi FK, Sobin LH, Torloni H (eds): International Classification of Tumors. Geneva, WHO, 1973.
13.
Kaplan E, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
https://doi.org/10.1080/01621459.1958.10501452
14.
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
[PubMed]
15.
Cox DR: Regression models and life-tables. J R Stat Soc 1972;34:187-220.
16.
Angulo JC, Lopez JI, Grignon DJ, et al: Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995;45:47-53.
[PubMed]
https://doi.org/10.1016/S0090-4295(95)96490-8
17.
Bernardini S, Billerey C, Martin M, et al: The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 2001;165:42-46.
[PubMed]
https://doi.org/10.1097/00005392-200101000-00011
18.
Orsola A, Trias I, Raventós CX, et al: Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005;48:231-238.
[PubMed]
https://doi.org/10.1016/j.eururo.2005.04.013
19.
Andius P, Johansson SL, Holmang S: Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 2007;70:758-762.
[PubMed]
https://doi.org/10.1016/j.urology.2007.06.638
20.
Mhawech-Fauceglia P, Fischer G, Alvarez V Jr, et al: Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int 2007;100:1182-1187.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2007.07090.x
21.
Faivre d'Arcier B, Celhay O, Safsaf A, et al: T1 bladder carcinoma: prognostic value of the muscularis mucosae invasion (T1a/T1b). A multicenter study by the French Urological Association (CCAFU). Prog Urol 2010;20:440-449.
[PubMed]
https://doi.org/10.1016/j.purol.2010.02.002
22.
van Rhijn BW, van der Kwast TH, Alkhateeb SS, et al: A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61:378-384.
[PubMed]
https://doi.org/10.1016/j.eururo.2011.10.026
23.
Platz CE, Cohen MB, Jones MP, et al: Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 1996;9:1035-1039.
[PubMed]
24.
Kondylis FI, Demirci S, Ladaga L, et al: Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol 2000;163:1120-1123.
[PubMed]
https://doi.org/10.1097/00005392-200004000-00013
25.
Shariat SF, Weizer AZ, Green A, et al: Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000;56:735-740.
[PubMed]
https://doi.org/10.1016/S0090-4295(00)00756-1
26.
Gohji K, Nomi M, Okamoto M, et al: Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999;53:308-313.
[PubMed]
https://doi.org/10.1016/S0090-4295(98)00480-4
27.
Cheng L, Weaver AL, Neumann RM, et al: Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999;86:1035-1043.
[PubMed]
https://doi.org/10.1002/(SICI)1097-0142(19990915)86:6<1035::AID-CNCR20>3.0.CO;2-D
28.
van Rhijn BW, Liu L, Vis AN, et al: Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int 2012;110:1169-1176.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2012.10996.x
29.
Oosterlinck W, Lobel B, Jakse G, Malmström PU, Stöckle M, Sternberg C; European Association of Urology (EAU) Working Group on Oncological Urology: Guidelines on bladder cancer. Eur Urol 2002;41:105-112.
[PubMed]
https://doi.org/10.1016/S0302-2838(01)00026-4
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.